A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors Lopez, J. S., Camidge, R., Iafolla, M., Rottey, S., Schuler, M., Hellmann, M., Balmanoukian, A., Dirix, L., Gordon, M., Sullivan, R., Henick, B. S., Drake, C., Wong, K., LoRusso, P., Ott, P., Fong, L., Schiza, A., Yachnin, J., Ottensmeier, C., Braiteh, F., Bendell, J., Leidner, R., Fisher, G., Jerusalem, G., Molenaar-Kuijsten, L., Schmidt, M., Laurie, S. A., Aljumaily, R., Rittmeyer, A., Gort, E., Melero, I., Mueller, L., Sabado, R., Twomey, P., Huang, J., Yadav, M., Zhang, J., Mueller, F., Derhovanessian, E., Sahin, U., Tuereci, O., Powles, T. AMER ASSOC CANCER RESEARCH. 2020

View details for DOI 10.1158/1538-7445.AM2020-CT301

View details for Web of Science ID 000590059302192